The expert panel agreed that a key barrier to wider access to CGM for individuals with T2D on non‐intensive insulin therapy is the lack of a clear value‐proposition that distinguishes the small proportion of individuals on basal or premixed insulin from the very large population of people with T2D on any therapy. Here, INS is linked to type 2 diabetes mellitus.